Publication:
The VIZIER project: Preparedness against pathogenic RNA viruses

dc.contributor.authorB. Coutarden_US
dc.contributor.authorA. E. Gorbalenyaen_US
dc.contributor.authorE. J. Snijderen_US
dc.contributor.authorA. M. Leontovichen_US
dc.contributor.authorA. Pouponen_US
dc.contributor.authorX. De Lamballerieen_US
dc.contributor.authorR. Charrelen_US
dc.contributor.authorE. A. Goulden_US
dc.contributor.authorS. Guntheren_US
dc.contributor.authorH. Norderen_US
dc.contributor.authorB. Klempaen_US
dc.contributor.authorH. Bourhyen_US
dc.contributor.authorJ. Rohayemen_US
dc.contributor.authorE. L'hermiteen_US
dc.contributor.authorP. Nordlunden_US
dc.contributor.authorD. I. Stuarten_US
dc.contributor.authorR. J. Owensen_US
dc.contributor.authorJ. M. Grimesen_US
dc.contributor.authorP. A. Tuckeren_US
dc.contributor.authorM. Bolognesien_US
dc.contributor.authorA. Mattevien_US
dc.contributor.authorM. Collen_US
dc.contributor.authorT. A. Jonesen_US
dc.contributor.authorJ. Åqvisten_US
dc.contributor.authorT. Ungeen_US
dc.contributor.authorR. Hilgenfelden_US
dc.contributor.authorG. Bricogneen_US
dc.contributor.authorJ. Neytsen_US
dc.contributor.authorP. La Collaen_US
dc.contributor.authorG. Puerstingeren_US
dc.contributor.authorJ. P. Gonzalezen_US
dc.contributor.authorE. Leroyen_US
dc.contributor.authorC. Cambillauen_US
dc.contributor.authorJ. L. Rometteen_US
dc.contributor.authorB. Canarden_US
dc.contributor.otherUniversite de Provence Aix-Marseille 1en_US
dc.contributor.otherCNRS Centre National de la Recherche Scientifiqueen_US
dc.contributor.otherCenter of Infectious Diseasesen_US
dc.contributor.otherFaculte de Medecine de Marseille Universite de la Mediterraneeen_US
dc.contributor.otherCentre for Ecology & Hydrologyen_US
dc.contributor.otherSwedish Institute for Infectious Disease Controlen_US
dc.contributor.otherInstitute of Virology Slovak Academy of Sciencesen_US
dc.contributor.otherInstitut Pasteur, Parisen_US
dc.contributor.otherBernhard Nocht Institut fur Tropenmedizin Hamburgen_US
dc.contributor.otherDresden University Faculty of Medicine and University Hospital Carl Gustav Carusen_US
dc.contributor.otherBioXtalen_US
dc.contributor.otherUniversity of Oxforden_US
dc.contributor.otherDeutsche Elektronen-Synchrotronen_US
dc.contributor.otherUniversita degli Studi di Milanoen_US
dc.contributor.otherUniversita degli Studi di Paviaen_US
dc.contributor.otherCSIC - Instituto de Biologia Molecular de Barcelona (IBMB)en_US
dc.contributor.otherGlobal Phasing Ltden_US
dc.contributor.otherUppsala Biomedicinska Centrumen_US
dc.contributor.otherUniversität zu Lübecken_US
dc.contributor.otherKU Leuvenen_US
dc.contributor.otherUniversita degli Studi di Cagliarien_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherIRD-R178en_US
dc.contributor.otherUniversity of Innsbrucken_US
dc.contributor.otherLomonosov Moscow State Universityen_US
dc.contributor.otherStockholms universiteten_US
dc.date.accessioned2018-07-12T02:31:22Z
dc.date.available2018-07-12T02:31:22Z
dc.date.issued2008-04-01en_US
dc.description.abstractLife-threatening RNA viruses emerge regularly, and often in an unpredictable manner. Yet, the very few drugs available against known RNA viruses have sometimes required decades of research for development. Can we generate preparedness for outbreaks of the, as yet, unknown viruses? The VIZIER (VIral enZymes InvolvEd in Replication) (http://www.vizier-europe.org/) project has been set-up to develop the scientific foundations for countering this challenge to society. VIZIER studies the most conserved viral enzymes (that of the replication machinery, or replicases) that constitute attractive targets for drug-design. The aim of VIZIER is to determine as many replicase crystal structures as possible from a carefully selected list of viruses in order to comprehensively cover the diversity of the RNA virus universe, and generate critical knowledge that could be efficiently utilized to jump-start research on any emerging RNA virus. VIZIER is a multidisciplinary project involving (i) bioinformatics to define functional domains, (ii) viral genomics to increase the number of characterized viral genomes and prepare defined targets, (iii) proteomics to express, purify, and characterize targets, (iv) structural biology to solve their crystal structures, and (v) pre-lead discovery to propose active scaffolds of antiviral molecules. © 2007 Elsevier B.V. All rights reserved.en_US
dc.identifier.citationAntiviral Research. Vol.78, No.1 (2008), 37-46en_US
dc.identifier.doi10.1016/j.antiviral.2007.10.013en_US
dc.identifier.issn01663542en_US
dc.identifier.other2-s2.0-40849111934en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/19354
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=40849111934&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleThe VIZIER project: Preparedness against pathogenic RNA virusesen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=40849111934&origin=inwarden_US

Files

Collections